Literature DB >> 22735949

Engineering of affibody molecules for therapy and diagnostics.

Joachim Feldwisch1, Vladimir Tolmachev.   

Abstract

Affibody molecules are small and robust non-immunoglobulin affinity ligands capable of binding to a wide range of protein targets. They are selected from combinatorial libraries based on a 58 amino acid, three-alpha-helical Z-domain scaffold. They share no sequence or structural homologies to antibodies and in contrast to antibodies they can be functionally produced both by peptide synthesis and by recombinant expression in Escherichia coli. Protein engineering is used to adapt Affibody molecules binding to a target of interest to the specific demands imposed by the intended application. Obviously, the optimal molecule for molecular imaging will be different from the optimal molecule for therapy. Here, we describe general strategies to optimize Affibody molecules for diagnostic imaging and therapy applications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22735949     DOI: 10.1007/978-1-61779-921-1_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  37 in total

1.  Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer.

Authors:  Lawrence A Stern; Brett A Case; Benjamin J Hackel
Journal:  Curr Opin Chem Eng       Date:  2013-11       Impact factor: 5.163

2.  Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use.

Authors:  Kimberley S Samkoe; Jason R Gunn; Kayla Marra; Sally M Hull; Karen L Moodie; Joachim Feldwisch; Theresa V Strong; Daniel R Draney; P Jack Hoopes; David W Roberts; Keith Paulsen; Brian W Pogue
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

3.  Preclinical imaging of epidermal growth factor receptor with ABY-029 in soft-tissue sarcoma for fluorescence-guided surgery and tumor detection.

Authors:  Kimberley S Samkoe; Hira S Sardar; Brent D Bates; Niki N Tselepidakis; Jason R Gunn; Kevin A Hoffer-Hawlik; Joachim Feldwisch; Brian W Pogue; Keith D Paulsen; Eric R Henderson
Journal:  J Surg Oncol       Date:  2019-04-04       Impact factor: 3.454

Review 4.  Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.

Authors:  Kelly E Henry; Gary A Ulaner; Jason S Lewis
Journal:  PET Clin       Date:  2017-07

Review 5.  Protein scaffolds: antibody alternatives for cancer diagnosis and therapy.

Authors:  Renli Luo; Hongguang Liu; Zhen Cheng
Journal:  RSC Chem Biol       Date:  2022-05-25

Review 6.  Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.

Authors:  Xianwen Hu; Dandan Li; Yujie Fu; Jiashen Zheng; Zelong Feng; Jiong Cai; Pan Wang
Journal:  Front Oncol       Date:  2022-06-15       Impact factor: 5.738

Review 7.  Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; Despina Yancopoulou; Antonio Risitano; John D Lambris
Journal:  Expert Rev Hematol       Date:  2014-09-02       Impact factor: 2.929

Review 8.  Ultrasound contrast materials in cardiovascular medicine: from perfusion assessment to molecular imaging.

Authors:  Alexander L Klibanov
Journal:  J Cardiovasc Transl Res       Date:  2013-08-03       Impact factor: 4.132

9.  Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity.

Authors:  Joanna Strand; Patrik Nordeman; Hadis Honarvar; Mohamed Altai; Anna Orlova; Mats Larhed; Vladimir Tolmachev
Journal:  ChemistryOpen       Date:  2015-01-12       Impact factor: 2.911

Review 10.  Improvement on Permeability of Cyclic Peptide/Peptidomimetic: Backbone N-Methylation as A Useful Tool.

Authors:  Yang Li; Wang Li; Zhengshuang Xu
Journal:  Mar Drugs       Date:  2021-05-27       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.